PepGen Inc. (PEPG)
3.78
-0.15
(-3.82%)
USD |
NASDAQ |
Nov 20, 16:00
3.79
+0.01
(+0.26%)
After-Hours: 20:00
PepGen Research and Development Expense (TTM) : 52.70M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 52.70M |
| June 30, 2026 | 51.51M |
| March 31, 2026 | 57.34M |
| December 31, 2025 | 69.65M |
| September 30, 2025 | 74.71M |
| June 30, 2025 | 78.97M |
| March 31, 2025 | 85.61M |
| December 31, 2024 | 74.97M |
| September 30, 2024 | 72.34M |
| June 30, 2024 | 75.19M |
| March 31, 2024 | 67.09M |
| Date | Value |
|---|---|
| December 31, 2023 | 66.94M |
| September 30, 2023 | 64.02M |
| June 30, 2023 | 59.65M |
| March 31, 2023 | 57.15M |
| December 31, 2022 | 53.58M |
| September 30, 2022 | 45.06M |
| June 30, 2022 | 34.90M |
| March 31, 2022 | 26.29M |
| December 31, 2021 | 16.08M |
| September 30, 2021 | 11.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Replimune Group, Inc. | 188.02M |
| Korsana Biosciences, Inc. | 43.39M |
| IRulya Therapeutics, Inc. | 30.76M |
| Q32 Bio, Inc. | 15.94M |
| Bridgebio Oncology Therapeutics, Inc. | 156.69M |